Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Inclusion Criteria:

• Starting treatment with monoclonal antibodies: nivolumab, pembrolizumab ipilimumab,bevacizumab, trastuzumab, durvalumab or atezolizumab.
• 18 years and older.
• No known history of increased susceptibility to immunological reactions.
• Subject is able and willing to sign the Informed Consent Form prior to screeningevaluations.

Exclusion Criteria:

• Other research medication within 4 weeks of the start of the study.
• Inclusion in medical research in which the administration of medication should followits stated times and dosages of infusions
• Dosage deviates from standard protocol
• Patients whom receive drugs through a central venous catheter (and for exampleporth-a-cath).